December 4, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces the following appointments to committees of the Board with effect from December 3, 2015:
Audit, Compliance & Risk Committee
1. Each director will serve as a member of the respective Board committee.
2. Dr. Gillis has served as an interim member of the Audit, Compliance & Risk Committee since December 3, 2014.
Senior Assistant Company Secretary
For further information please contact:
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.